BioPlus Acquisition Corp.
BIOS · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $708,900 | $817,200 |
| % Growth | – | -100% | -13.3% | – |
| Cost of Goods Sold | $1,171 | $0 | $465,900 | $547,900 |
| Gross Profit | -$1,171 | $0 | $243,000 | $269,300 |
| % Margin | – | – | 34.3% | 33% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $47,300 | $63,300 |
| SG&A Expenses | $1 | $0 | $47,300 | $63,300 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $189,600 | $220,800 |
| Operating Expenses | $1 | $0 | $236,900 | $284,100 |
| Operating Income | -$1,171 | -$0 | -$108,500 | -$52,700 |
| % Margin | – | – | -15.3% | -6.4% |
| Other Income/Exp. Net | $3,167 | $0 | $57,500 | -$14,700 |
| Pre-Tax Income | $1,996 | -$0 | -$51,000 | -$67,400 |
| Tax Expense | -$3,167 | $0 | $600 | $63,600 |
| Net Income | $5,163 | -$0 | -$51,600 | -$131,000 |
| % Margin | – | – | -7.3% | -16% |
| EPS | 0.009 | -0.022 | -0.4 | -1.06 |
| % Growth | 138.7% | 94.5% | 62.3% | – |
| EPS Diluted | 0.2 | -0.022 | -0.4 | -1.06 |
| Weighted Avg Shares Out | 597,792 | 7 | 127,900 | 123,800 |
| Weighted Avg Shares Out Dil | 26,435 | 7 | 127,900 | 123,800 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,167 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | -$57,400 | -$52,100 |
| Depreciation & Amortization | $228 | $237 | $23,600 | $27,730 |
| EBITDA | -$1,171 | $0 | -$84,900 | -$24,970 |
| % Margin | – | – | -12% | -3.1% |